EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system

Roche's xCELLigence RTCA System is being used in the European Union's SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) initiative to run five years from 2011 to 2016. As of 2013, animal experiments are no longer permitted for use in toxicology testing in the cosmetic industry. Significant progress has been made in recent years to develop alternatives to in vivo toxicity tests for assessing human safety of new products and their ingredients. At present, it is however not possible to completely replace animal testing. This is especially true when testing the effects of repeated doses over longer periods of time.

A SEURAT-sponsored research team comprising Paul Jennings at the Department of Physiology and Medical Physics, Innsbruck Medical University (Austria), and Alex Seiler and Manfred Watzele at Roche Penzberg (Germany), used continuous real-time impedance measurements with the xCELLigence System to investigate renal epithelial monolayer formation and barrier function. To test repeated dose effects, a human renal proximal tubule cell line (RPTEC/TERT1, Evercyte GmbH Vienna) was cultured on electronic sensor-containing E-Plates 96.  Cell impedance was monitored over several weeks in culture, and the effect of nephrotoxin treatment on cell impedance was investigated. Findings showed that the three different nephrotoxins initially increased impedance values as epithelial cell morphology was altered, followed by a decrease in impedance due to cell death.

The xCELLigence System was shown to be a sensitive, non-invasive tool for monitoring repeated dose effects on epithelial cell function and cytotoxicity. Unlike the more laborious transepithelial electrical resistance (TEER) assay, this in vitro assay is a simple, automated, non-invasive, functional readout with very high temporal resolution.  Assays such as this will we be beneficial in efforts to replace animal testing for long-term repeat dose regimes.

Source:

Roche Diagnostics GmbH

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Roche Sequencing and Life Science. (2019, June 24). EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system. News-Medical. Retrieved on May 18, 2024 from https://www.news-medical.net/news/20120329/EUs-Safety-Evaluation-Ultimately-Replacing-Animal-Testing-initiative-tests-Roches-xCELLigence-system.aspx.

  • MLA

    Roche Sequencing and Life Science. "EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system". News-Medical. 18 May 2024. <https://www.news-medical.net/news/20120329/EUs-Safety-Evaluation-Ultimately-Replacing-Animal-Testing-initiative-tests-Roches-xCELLigence-system.aspx>.

  • Chicago

    Roche Sequencing and Life Science. "EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system". News-Medical. https://www.news-medical.net/news/20120329/EUs-Safety-Evaluation-Ultimately-Replacing-Animal-Testing-initiative-tests-Roches-xCELLigence-system.aspx. (accessed May 18, 2024).

  • Harvard

    Roche Sequencing and Life Science. 2019. EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system. News-Medical, viewed 18 May 2024, https://www.news-medical.net/news/20120329/EUs-Safety-Evaluation-Ultimately-Replacing-Animal-Testing-initiative-tests-Roches-xCELLigence-system.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Roche establishes strategic alliance with Diagnostic Laboratory Services